SynthesisReviews in endocrine & metabolic disorders2025
Body mass index and body composition changes in transgender people undergoing gender-affirming hormone therapy: a systematic review and meta-analysis.
Synthesis in Reviews in endocrine & metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07481942 (Body Composition Adaptations Following Initiation of Gender-Affirming Hormone Therapy in Transgender Populations.), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Body Composition Adaptations Following Initiation of Gender-Affirming Hormone Therapy in Transgender Populations.
Who cites it
2 citing papers in PubMed.
- Nutritional Monitoring During Gender-Affirming Hormone Therapy: Body Composition and Metabolic Implications.Nutrients · 2026Review
- One-year changes in body composition and phase angle during feminizing gender-affirming hormone therapy: a longitudinal and comparative study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gender-affirming hormone therapy (GAHT) uses sex steroid hormones to induce desired physical changes, improving the quality of life of transgender individuals. While generally considered safe, its effects on body composition and adipose tissue remain a topic of debate. The aim of this review was to verify whether GAHT is associated with weight gain and body composition in transgender individuals. This is a systematic review with meta-analysis (April-September 2022, updated March 2025) following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including cohort, case‒control, and clinical trial studies from four databases. The outcomes analyzed included body mass index (BMI), body fat (BF), lean mass (LM), and waist circumference (WC). Among the 1,896 identified studies, 29 were included in the systematic review, and 28 were included in the meta-analysis. GAHT increased BMI in assigned male at birth (AMAB) individuals (0.55 kg/m², 95% CI: 0.14-0.97) and assigned female at birth (AFAB) individuals (0.92 kg/m², 95% CI: 0.55-1.29). The AMAB participants presented a reduction in LM (-1.81 kg, 95% CI: -3.15, -0.47) and an increase in BF (4.27 kg, 95% CI: 3.15-5.39), whereas the AFAB individuals presented an increase in LM (4.98 kg, 95% CI: 4.06-5.91) and a decrease in BF (-2.13 kg, 95% CI: -3.52, -0.75). No significant changes in WC were observed in either group. According to the GRADE assessment, the certainty of evidence was moderate for BMI and low to very low for changes in waist circumference, lean mass, and fat mass. GAHT is associated with increased BMI and body composition changes. These alterations align with the expected outcomes for transgender individuals and do not appear to be directly linked to cardiovascular risks.
Indexed as
Identifiers
40569560What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.